Previous 10 | Next 10 |
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter 2020 after market close on Monday, November 9, 2020. Company managemen...
~ Two oral abstracts highlight positive findings from pivotal studies for the treatment of sebaceous hyperplasia and cutaneous non-genital warts with the CellFX ® System ~ ~ Two posters showcase favorable results of the CellFX System for the treatment of plantar warts...
Gainers: Greenpro Capital (GRNQ) +85%.MyoKardia (MYOK) +58%.Westwater Resources (WWR) +53%.Eidos Therapeutics (EIDX) +40%.Scully Royalty (SRL) +34%.Enlivex Therapeutics (ENLV) +28%.Humanigen (HGEN) +24%.Corvus Pharmaceuticals (CRVS) +22%.Piedmont Lithium (PLL) +22%.Pulse Biosciences (PLS...
Completes First Procedures in CellFX System Specific Indication Study Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA Investigational Device Exemption (IDE) ...
Pulse Biosciences ([[PLSE]] +0.7%) announces the receipt of Medical Device Single Audit Program certification.The program allows the conduct of a single regulatory audit of a medical device manufacturer’s quality management system."On the path to commercializing the CellFX® S...
Achieving ISO-13485:2016 MDSAP Certification Affirms the Company’s Quality Management Systems Meet FDA, Health Canada and CE Mark Requirements Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS&...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the Compensation Committee of the Company’s Board of ...
Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to virtually participate in the upcoming H.C. Wainwright Global Investment Conference. Management is scheduled to present ...
The following healthcare companies have filed for mixed shelf offerings: More news on: Pulse Biosciences, Inc., ContraFect Corporation, Larimar Therapeutics, Inc., Healthcare stocks news, , Read more ...
Image source: The Motley Fool. Pulse Biosciences, Inc. (NASDAQ: PLSE) Q2 2020 Earnings Call Aug 10, 2020 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company managemen...
2024-07-15 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...